Meda Pharmaceuticals
📋 Case Summary
What happened An anonymous company representative complained about Meda Pharmaceuticals Limited’s promotion of Aldara (imiquimod cream) and the activities of its representatives. Concerns included: (1) call-rate expectations introduced in January 2008; (2) use of a letter to doctors (a “GPwSI letter”) to gain appointments; and (3) alleged encouragement to promote Aldara off licence to maxillofacial units and plastic surgeons. The Panel reviewed salesforce briefing materials and emails about customer targets, including a slide stating call frequency was to be within ABPI guidelines and setting quarterly coverage/frequency expectations for 100 target GPs. The Panel considered the Code’s supplementary information that unsolicited calls on a doctor/prescriber should normally not exceed three per year on average (with specified exclusions), and noted briefing material should distinguish between expected call rates and contact rates. For the letter, Meda stated it had been certified and pres
📌 Clauses Breached
15.9,3.2